Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 14;20(18):5320-30.
doi: 10.3748/wjg.v20.i18.5320.

Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities

Mina Shaker  1 , Adam Tabbaa  1 , Mazen Albeldawi  1 , Naim Alkhouri  1
Affiliations
Review

Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities

Mina Shaker et al. World J Gastroenterol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming rapidly one of the most common indications for orthotopic liver transplantation in the world. Development of graft steatosis is a significant problem during the post-transplant course, which may happen as a recurrence of pre-existing disease or de novo NAFLD. There are different risk factors that might play a role in development of graft steatosis including post-transplant metabolic syndrome, immune-suppressive medications, genetics and others. There are few studies that assessed the effects of NAFLD on graft and patient survival; most of them were limited by the duration of follow up or by the number of patients. With this review article we will try to shed light on post-liver transplantation NAFLD, significance of the disease, how it develops, risk factors, clinical course and treatment options.

Keywords: Liver cirrhosis; Liver transplantation; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Development of post-transplant nonalcoholic fatty liver disease depends on a combination of host and graft factors. Schematic representation of potential mechanistic pathways that lead to development of post-transplant nonalcoholic fatty liver disease including genetic background, metabolic syndrome, insulin resistance and the effects of immunosuppressive medications. Recurrent of de novo nonalcoholic steatohepatitis (NASH) may eventually lead to the development of graft cirrhosis and the need for re-transplantation. IL28B: Interleukin 28B; PNPLA3: Patatin-like phospholipase domain-containing protein 3; DM: Diabetes mellitus; HTN: Hypertension.
See this image and copyright information in PMC

References

    1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.e1; quiz e60. - PubMed
    1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395. - PubMed
    1. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578–584. - PubMed
    1. Desai HG. Cryptogenic cirrhosis: a vanishing entity. J Assoc Physicians India. 2009;57:751–754, 759. - PubMed
    1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137–145. - PubMed

MeSH terms